Sarcoma as Second Cancer in a Childhood Cancer Survivor: Case Report, Large Population Analysis and Literature Review

Nguyen, Thinh H.; Makena, Monish R.; Yavvari, Siddhartha; Kaur, Maninder; Pham, Teresia; Urias, Eduardo; Panapitiya, Narendra; Al-Rahawan, Mohamad M.

doi:10.3390/medicina56050224

Cited by 8 publications

(4 citation statements)

References 44 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the ionizing radiation that is used to treat approximately 50% of cancers is a double-edged sword in that it is also a carcinogen itself [ 2 ]. Thus, the improved survival comes at the cost of an elevated risk of developing radiation-induced second malignant neoplasms (SMNs), especially when treatment takes place during childhood and adolescence [ 3 , 4 , 5 , 6 , 7 , 8 ]. SMN risk could be included as a factor in the process of treatment planning optimization, but to this end the dose–response relationship must be known.…”

Section: Introductionmentioning

confidence: 99%

Cell Type-Specific Patterns in the Accumulation of DNA Damage Following Multifractional Radiation Exposure

Akuwudike

Tartas

López-Riego

et al. 2022

IJMS

View full text Add to dashboard Cite

Predicting the risk of second malignant neoplasms is complicated by uncertainties regarding the shape of the dose–response relationship at high doses. Limited understanding of the competitive relationship between cell killing and the accumulation of DNA lesions at high doses, as well as the effects of other modulatory factors unique to radiation exposure during radiotherapy, such as dose heterogeneity across normal tissue and dose fractionation, contribute to these uncertainties. The aim of this study was to analyze the impact of fractionated irradiations on two cell systems, focusing on the endpoints relevant for cancer induction. To simulate the heterogeneous dose distribution across normal tissue during radiotherapy, exponentially growing VH10 fibroblasts and AHH-1 lymphoblasts were irradiated with 9 and 12 fractions (VH10) and 10 fractions (AHH-1) at 0.25, 0.5, 1, or 2 Gy per fraction. The effects on cell growth, cell survival, radiosensitivity and the accumulation of residual DNA damage lesions were analyzed as functions of dose per fraction and the total absorbed dose. Residual γH2AX foci and other DNA damage markers (micronuclei, nuclear buds, and giant nuclei) were accumulated at high doses in both cell types, but in a cell type-dependent manner. The competitive relationship between cell killing and the accumulation of carcinogenic DNA damage following multifractional radiation exposure is cell type-specific.

show abstract

Section: Introductionmentioning

confidence: 99%

Cell Type-Specific Patterns in the Accumulation of DNA Damage Following Multifractional Radiation Exposure

Akuwudike

Tartas

López-Riego

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Twenty-four of the 38 patients with SMNs following HB treatment reported were identified by the authors' institutional review (Tables 1-4) 12,13,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] ; and of those, 17 were previously reported but appear here with additional clinical data. 12,13,24,29 Patients from 4 reports were omitted due to a lack of sufficient clinical details available to conclude that they had not been reported previously.…”

Section: Resultsmentioning

confidence: 99%

Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature

Trobaugh-Lotrario,

Watanabe,

O’Neill

et al. 2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Treatment intensification has improved survival in patients with hepatoblastoma (HB); however, these treatments are associated with an increased risk of late effects, including second malignant neoplasms (SMNs). Data is limited regarding SMNs following HB treatment. Cases of SMNs following treatment for HB reported in the literature and from personal communication were analyzed to further assess this late effect. Thirty-eight patients were identified. The median age at diagnosis of HB was 16 months (range: 3 to 168 mo). All patients had received a platinum agent, and almost all had anthracycline exposure. The SMNs reported were hematopoietic malignancies (n=19), solid tumors (n=12), and post-transplant lymphoproliferative disorder (n=7). Of the 36 patients with outcome data, 19 survived. SMNs following HB treatment were primarily seen in patients with chemotherapy exposure, a history of liver transplantation, hereditary tumor predisposition syndromes, and/or a history of radiation treatment. Hematopoietic malignancies were the most common SMN reported in this cohort and were diagnosed earlier than other SMNs. Prospective collection of data through a companion late effects study or international registry could be used to further evaluate the rates and risks of SMNs as well as tumor predisposition syndromes in patients treated for HB.

show abstract

“…Including the current reports, thirty-eight patients with SMNs following treatment for HB have been reported (Tables 1-4). [12][13][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] This included 24 patients from the authors' experiences: acute myeloblastic leukemia (AML), n=7; acute lymphoblastic leukemia (ALL), n=3; myelodysplastic syndrome (MDS), n=2; posttransplant lymphoproliferative disorder (PTLD), n=3; T-cell lymphoma, n=1; renal cell carcinoma, n=1; medulloblastoma, n=1; colon carcinoma, n=1; nephroblastoma, n=1; thyroid carcinoma, n=1, hepatocellular carcinoma, n=1. Seventeen of these 23 patients (Poland-1 to 3, Japan-1 to 12, Germany-1, USA-4) were previously reported but appear here with additional clinical data.…”

Section: Resultsmentioning

confidence: 99%

Second malignant neoplasms following treatment for hepatoblastoma: an international report and review of the literature

Trobaugh-Lotrario,

Watanabe,

O'Neill

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Treatment intensification has improved survival in patients with hepatoblastoma (HB); however, these treatments are associated with an increased risk of late effects including second malignant neoplasms (SMNs). Data is limited regarding SMNs following HB treatment. Methods: Cases of SMNs following treatment for HB reported in the literature and from personal communication were analyzed to further assess this late effect. Results: Thirty-eight patients were identified. Median age at diagnosis of HB was 16 months (range: 3 to 168 months). All patients had received a platinum agent, and almost all had anthracycline exposure. Of 12 patients with a known history of liver transplantation for primary resection of their HB, the majority had post-transplant lymphoproliferative disorder (PTLD) (n=7). The most common SMNs reported were non-PTLD hematopoietic malignancies (n=19). Solid tumors were seen in 12 patients: peripheral neuroectodermal tumor/Ewing sarcoma (3); and one each for renal cell carcinoma, nephroblastoma, colorectal carcinoma, thyroid carcinoma, medulloblastoma, clear cell sarcoma-like tumor, hepatocellular carcinoma, osteosarcoma, and malignant schwannoma. Of 36 patients with data, nineteen survived. Conclusions: SMNs following HB treatment were seen in patients with anthracycline (and cisplatin) exposure, hereditary tumor predisposition syndromes, and/or history of liver transplantation. Hematopoietic malignancies were the most common SMN reported in this cohort and were diagnosed earlier than other SMNs. Prospective collection of data via a companion late effects study or international registry could be used to further evaluate rates and risks of SMNs as well as tumor predisposition syndromes in patients treated for HB.

show abstract

Sarcoma as Second Cancer in a Childhood Cancer Survivor: Case Report, Large Population Analysis and Literature Review

Cited by 8 publications

References 44 publications

Cell Type-Specific Patterns in the Accumulation of DNA Damage Following Multifractional Radiation Exposure

Cell Type-Specific Patterns in the Accumulation of DNA Damage Following Multifractional Radiation Exposure

Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature

Second malignant neoplasms following treatment for hepatoblastoma: an international report and review of the literature

Contact Info

Product

Resources

About